Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder
Jan 25, 2023 Leah Kuntz SPL026 with supportive therapy sees positive results in patients with major depressive disorder. metamorworks/AdobeStock In the first placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression, intravenous (IV) N,N-Dimethyltryptamine (DMT)—SPL026—with supportive therapy for the treatment of major depressive disorder (MDD), met the primary endpoint and demonstrated a …
Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder Read More »
